Last reviewed · How we verify
NCT04195568: EVOLVE
Evaluation of Safety and Effectiveness of Stryker Surpass Evolve™ Flow Diverter System
NA trial testing Surpass Evolve Flow Diverter System in Aneurysm, Intracranial in 248 participants. Participants enrolled and being followed up; not accepting new ones.
14 July 2025
Quick facts
| Lead sponsor | Stryker Neurovascular |
|---|---|
| Phase | NA |
| Status | Active, enrolled |
| Study type | INTERVENTIONAL |
| Allocation | na |
| Design | single group |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 248 |
| Start date | 7 July 2020 |
| Primary completion | 14 July 2025 |
| Estimated completion | 13 September 2028 |
| Sites | 37 locations across Canada, United States, Australia |
Drugs / interventions tested
- Surpass Evolve Flow Diverter System
Conditions studied
- Aneurysm, Intracranial — all drugs for Aneurysm, Intracranial →
Sponsor
Stryker Neurovascular — full company profile →
Who can join
Adults 18 to 80, any sex, with Aneurysm, Intracranial. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The primary objective of this study is to evaluate the safety and effectiveness of the Surpass™ Evolve Flow Diverter System in the treatment of unruptured, wide-neck intracranial aneurysms measuring ≤ 12 mm and located on the ICA or its branches
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT04195568
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Aneurysm, Intracranial
Currently open trials in the same condition.
- NCT06872684 — Safety and Efficacy of Endovascular Treatment of Intracranial Aneurysms With Surpass Elite With GUARDian Flow Diverter ( · NA · recruiting
- NCT06446778 — Pipeline Embolization for Intracranial Aneurysms · recruiting
Other Stryker Neurovascular trials
Trials by the same sponsor.
- NCT06872684 — Safety and Efficacy of Endovascular Treatment of Intracranial Aneurysms With Surpass Elite With GUARDian Flow Diverter ( · NA · recruiting
- NCT05544045 — China Surpass Streamline Post-Market Study · terminated
- NCT04380350 — Trenza Embolization Device for Intrasaccular Aneurysm Treatment · active not recruiting
- NCT04162483 — Safety and Performance of the Neuroform Atlas™ Stent System · unknown
- NCT04057352 — Citadel Embolization Device Study · NA · active not recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT04195568 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Stryker Neurovascular
- Last refreshed: 9 April 2026
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04195568.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing